Table 2 Combination of RDV and favipiravir has additive effect on the antiviral activity against SUDV and MARV infections in cells, as shown by the combination index (CI), excess volume, and synergy score values.

From: Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro

Viruses

Minimum CI

Median CI

Maximum CI

Synergy model

Excess volume

Synergy score

SUDV

0.57

1.12

1.34

Loewe Model

− 0.52

− 0.06

HSA Model

0.72

0.57

Bliss Model

− 0.78

− 0.23

MARV

0.88

1.02

1.09

Loewe Model

− 0.45

− 0.29

HSA Model

0.87

0.53

Bliss Model

0.02

− 0.08

  1. CI combination index, HSA highest single agent.
Back to article page